PhoreMost
PhoreMost is a biopharmaceutical company dedicated to 'Drugging the Undruggable®' by applying its proprietary SITESEEKER® technology to discover novel drug targets, especially in oncology and Targeted Protein Degradation (TPD). The company collaborates with industry partners to develop ground-breaking medicines and has a strong focus on expanding druggable space, utilizing advanced technologies including AI and protein structure prediction. With a mission to accelerate, diversify, and rationalize drug discovery, PhoreMost aims to unlock the next generation of medicines for challenging diseases.
Industries
Nr. of Employees
small (1-50)
PhoreMost
Cambridge, Cambridgeshire, United Kingdom, Europe
Products
Encoded mini-protein library assets for target discovery
High-diversity, DNA-encoded mini-protein library collections designed for pooled lentiviral delivery and phenotypic interrogation to reveal druggable sites and functional hits.
Internal degrader programme pipeline (preclinical-stage assets)
A pipeline of degrader-focused drug discovery programmes based on novel E3 ligase binders and heterobifunctional degrader chemistries progressing toward preclinical development.
Encoded mini-protein library assets for target discovery
High-diversity, DNA-encoded mini-protein library collections designed for pooled lentiviral delivery and phenotypic interrogation to reveal druggable sites and functional hits.
Internal degrader programme pipeline (preclinical-stage assets)
A pipeline of degrader-focused drug discovery programmes based on novel E3 ligase binders and heterobifunctional degrader chemistries progressing toward preclinical development.
Services
Phenotypic target discovery service using encoded mini-proteins
Application of large-scale, live-cell pooled mini-protein screening to identify phenotypically active targets and druggable binding pockets for partner drug discovery programmes.
Molecular glue discovery platform service
Systematic discovery and evaluation of molecular glue-like interactions using engineered mini-proteins to inform molecular glue degrader design and neosubstrate identification.
Collaborative drug discovery alliances
Multi-party collaborations applying phenotypic screening, computational analysis and degrader discovery capabilities to co-develop therapeutic programmes.
Phenotypic target discovery service using encoded mini-proteins
Application of large-scale, live-cell pooled mini-protein screening to identify phenotypically active targets and druggable binding pockets for partner drug discovery programmes.
Molecular glue discovery platform service
Systematic discovery and evaluation of molecular glue-like interactions using engineered mini-proteins to inform molecular glue degrader design and neosubstrate identification.
Collaborative drug discovery alliances
Multi-party collaborations applying phenotypic screening, computational analysis and degrader discovery capabilities to co-develop therapeutic programmes.
Expertise Areas
- Phenotypic target discovery
- Targeted protein degradation (TPD)
- Molecular glue discovery
- Encoded mini-protein library screening
Key Technologies
- Encoded lentiviral mini-protein libraries
- High-throughput pooled phenotypic screening
- Next-generation sequencing (NGS) readouts
- Functional genomics (CRISPR/RNAi) integration